IBD:人造甜味剂促进克罗恩病样肠炎的肠道变形菌,营养不良和髓过氧化物酶反应

2018-04-07 MedSci MedSci原创

流行病学研究表明,使用人造甜味剂会增加克罗恩病(CD)的风险。因此,研究人员试验性地量化了使用商业甜味剂(Splenda;成分三氯蔗糖麦芽糖糊精,1:99)对CD样肠炎的严重程度和使用SAMP1 / YitFc的肠微生物组变化的6周补充的影响( SAMP)小鼠。

背景

流行病学研究表明,使用人造甜味剂会增加克罗恩病(CD)的风险。因此,研究人员试验性地量化了使用商业甜味剂(Splenda;成分三氯蔗糖麦芽糖糊精,1:99)对CD样肠炎的严重程度和使用SAMP1 / YitFc的肠微生物组变化的6周补充的影响( SAMP)小鼠。

方法

宏基因组DNA测序首先用于表征易发生回肠炎的SAMP小鼠的微生物组测序。然后,实施16S rRNA微生物组测序,定量聚合酶链式反应,荧光原位杂交(FISH),细菌培养,立体显微镜,组织学和髓过氧化物酶(MPO)活性分析,以比较SAMP中的微生物组和回肠炎表型与对照补充Splenda后无回肠炎的AKR / J小鼠的小肠菌群。

结果

宏基因组学表明,SAMP小鼠具有富含拟杆菌的肠道微生物表型,并且实验表明,螺杆菌对回肠炎没有加剧作用。Splenda没有增加(立体显微镜/组织学)回肠炎的严重程度; 然而,生物化学方面,用Splenda处理的SAMP与未补充的小鼠(P <0.022)和健康的AKR小鼠相比,回肠MPO活性增加。Splenda 在所有小鼠中存在生态失调,并且大肠杆菌过度生长并且细菌浸润增加到SAMP小鼠的回肠固有层中。

结论

Splenda 在(富含杆菌肽的)回肠CD 的自发模型中促进肠道变形杆菌,生态失调和生化MPO反应性。研究结果表明,尽管Splenda可能促进CD易感和健康宿主并行微生物组的改变,但这并不导致MPO水平在健康小鼠,仅CD易感小鼠中升高。含有三氯半乳蔗糖/麦芽糖糊精的食物的消耗可能仅在具有促炎症倾向的个体(例如CD)中加剧MPO肠道反应性。

原始出处:
Alexander Rodriguez-Palacios. Et al. The Artificial Sweetener Splenda Promotes Gut Proteobacteria, Dysbiosis, and Myeloperoxidase Reactivity in Crohn's Disease-Like Ileitis. Inflammatory Bowel Diseases. 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1708119, encodeId=e81d1e081192f, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Sat Jan 26 22:44:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312019, encodeId=a72131201994, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Fri May 04 21:05:33 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305153, encodeId=849930515392, content=天然事物**的, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Thu Apr 12 20:02:22 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304348, encodeId=f980304348bd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Apr 10 05:56:05 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263467, encodeId=46b0126346eb5, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Apr 09 00:44:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303730, encodeId=5559303e30dc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sun Apr 08 06:16:05 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1708119, encodeId=e81d1e081192f, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Sat Jan 26 22:44:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312019, encodeId=a72131201994, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Fri May 04 21:05:33 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305153, encodeId=849930515392, content=天然事物**的, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Thu Apr 12 20:02:22 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304348, encodeId=f980304348bd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Apr 10 05:56:05 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263467, encodeId=46b0126346eb5, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Apr 09 00:44:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303730, encodeId=5559303e30dc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sun Apr 08 06:16:05 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
    2018-05-04 cscdliu

    学习了.谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1708119, encodeId=e81d1e081192f, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Sat Jan 26 22:44:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312019, encodeId=a72131201994, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Fri May 04 21:05:33 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305153, encodeId=849930515392, content=天然事物**的, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Thu Apr 12 20:02:22 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304348, encodeId=f980304348bd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Apr 10 05:56:05 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263467, encodeId=46b0126346eb5, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Apr 09 00:44:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303730, encodeId=5559303e30dc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sun Apr 08 06:16:05 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
    2018-04-12 易水河

    天然事物**的

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1708119, encodeId=e81d1e081192f, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Sat Jan 26 22:44:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312019, encodeId=a72131201994, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Fri May 04 21:05:33 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305153, encodeId=849930515392, content=天然事物**的, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Thu Apr 12 20:02:22 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304348, encodeId=f980304348bd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Apr 10 05:56:05 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263467, encodeId=46b0126346eb5, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Apr 09 00:44:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303730, encodeId=5559303e30dc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sun Apr 08 06:16:05 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
    2018-04-10 秀红

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1708119, encodeId=e81d1e081192f, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Sat Jan 26 22:44:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312019, encodeId=a72131201994, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Fri May 04 21:05:33 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305153, encodeId=849930515392, content=天然事物**的, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Thu Apr 12 20:02:22 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304348, encodeId=f980304348bd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Apr 10 05:56:05 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263467, encodeId=46b0126346eb5, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Apr 09 00:44:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303730, encodeId=5559303e30dc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sun Apr 08 06:16:05 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
    2018-04-09 bnurmamat
  6. [GetPortalCommentsPageByObjectIdResponse(id=1708119, encodeId=e81d1e081192f, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Sat Jan 26 22:44:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312019, encodeId=a72131201994, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Fri May 04 21:05:33 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305153, encodeId=849930515392, content=天然事物**的, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Thu Apr 12 20:02:22 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304348, encodeId=f980304348bd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Apr 10 05:56:05 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263467, encodeId=46b0126346eb5, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Apr 09 00:44:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303730, encodeId=5559303e30dc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sun Apr 08 06:16:05 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
    2018-04-08 121832a9m88暂无昵称

    学习了

    0

相关资讯

JCC:生物制剂的再诱导与剂量间隔缩短相比,在治疗克罗恩失应答上效果相同且更便宜。

在抗肿瘤坏死因子[TNF]治疗的二次失效反应[LOR]后的增加剂量增强治疗效果的最佳持续时间仍不清楚。抗-TNF再诱导涉及有限的强化治疗期,并且可能是重新获得应答的成本有效的手段。本研究旨在比较克罗恩病[CD]中继发性LOR的抗TNF再诱导和剂量间隔缩短[DIS]的有效性,耐用性和成本的差异。

IBD: 荷尔蒙波动对炎症性肠病症状严重度的影响的横断面队列研究

许多炎症性肠病(IBD)妇女报告在月经,怀孕和使用激素避孕药期间与疾病症状的改变与体内激素变化相关。我们的目标是在激素变异期间鉴定女性IBD症状炎症活动程度的波动。

JCC: 基于丹麦人群的关于克罗恩病患者疾病行为和部位的变化的研究

克罗恩病[CD]是一种慢性炎症性肠病,可导致诸如狭窄或穿透性疾病等并发症,最终导致手术。根据蒙特利尔分类,很少有基于人群的研究调查了疾病进展和CD手术的预测因素。本项研究旨在确定在丹麦人群初始队列中与复杂CD相关的临床预测因子。

JCC: 生物标志物与克罗恩病患者的内镜结果的相关性

克罗恩病(CD)的治疗正朝向使用粪钙卫蛋白(FC)和C-反应蛋白(CRP)生物标志物预测的粘膜愈合治疗目标迈进,以优化治疗。CALM表明,基于症状和生物标志物的严格治疗方案,治疗升级的患者的内镜治疗效果优于常规治疗的患者,但尚未建立最佳生物标志物截断值来预测粘膜愈合。在CALM的这项分析中,研究了内镜结果与FC和CRP临界值的相关性。

JCC: Ustekinumab治疗克罗恩病患者接受腹部手术的术后结局分析

Ustekinumab是一种靶向IL-12和IL-23的单克隆抗体,用于治疗成人克罗恩病[CD]。研究人员确定了在腹部手术前12周内接受Ustekinumab的CD患者与接受抗肿瘤坏死因子[TNF]制剂的患者相关资料,并记录术后30天的感染并发症发生率。

Am J Gastroenterology:回盲部吻合术类型对术后克罗恩病患者的长期功能状态,生活质量和保健利用有显着影响,与炎症复发无关

克罗恩氏病(CD)肠切除术后的吻合口重建可采用侧-侧吻合(STSA;抗蠕动方向)或端-端吻合术(ETEA)。本项研究的目的是确定这两种吻合技术对术后CD患者长期临床状态的影响。